Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bristol Myers Squibb Company (BMY) vs Organon & Co. (OGN)

Bristol Myers Squibb Company and Organon & Co. are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $125.9B against $3.6B — 35.0× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.8× against 17.4×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against −2.45%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 3.41%) and the higher return on invested capital (13.7% vs 6.11%). Both pay a dividend; Organon & Co. yields more (6.88% vs 5.04%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 15 and Organon & Co. on 8.

Valuation

Metric BMY OGN Drug Manufacturers General median
P/E 13.85 17.38 24.72
P/S 2.61 0.59 3.35
P/B 5.75 3.58 5.00
Price to free cash flow 11.22 7.77 17.68
EV/EBITDA 10.63 7.82 13.91
EV/Sales 3.26 1.80 3.95
Earnings yield 7.22% 5.75% 2.92%
Free cash flow yield 8.91% 12.87% 4.42%

Profitability

Metric BMY OGN Drug Manufacturers General median
Gross margin 70.16% 52.68% 72.77%
Operating margin 24.22% 13.45% 18.90%
Net margin 18.87% 3.41% 8.27%
Free cash flow margin 23.26% 7.57% 17.25%
Return on equity 46.63% 24.04% 6.97%
Return on assets 10.18% 1.57% 2.76%
Return on invested capital 13.69% 6.11% 6.30%

Growth

Metric BMY OGN Drug Manufacturers General median
Revenue growth (TTM) 3.11% (2.45%) 6.79%
EPS growth (last fiscal year) 178.46% (78.38%) —
Revenue growth, 5-year CAGR 2.54% (0.99%) 3.98%
Net income growth, 5-year CAGR 0.00% (38.70%) 0.42%

Health

Metric BMY OGN Drug Manufacturers General median
Debt to equity 1.93 8.50 0.63
Current ratio 1.53 1.95 1.32
Net debt to EBITDA 2.58 5.62 1.15

Dividend

Metric BMY OGN Drug Manufacturers General median
Dividend yield 5.04% 6.88% 3.57%
Payout ratio 0.60 0.38 0.53

Size

Metric BMY OGN Drug Manufacturers General median
Market cap 125.91b 3.60b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack